CLNS1A Antibody

What is CLNS1A and what are its primary biological functions?

CLNS1A (Chloride Channel, Nucleotide-Sensitive, 1A), also known as Methylosome subunit pICln, functions in multiple regulatory pathways. This protein:

• Acts as a chaperone that regulates the assembly of spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs)

• Participates in the methylation of Sm proteins as part of the methylosome complex

• Functions as a chloride current regulator when associated with the plasma membrane

• Plays roles in platelet activation and cytoskeletal organization

• Forms part of the methylosome complex with PRMT5 and WDR77

• Has been implicated in transcriptional regulation mediated by ligand-bound nuclear hormone receptors

The protein has a molecular weight of approximately 26.2 kDa and belongs to the pICln (TC 1.A.47) superfamily .

What types of CLNS1A antibodies are available and how do they differ?

CLNS1A antibodies vary across several key parameters that affect their experimental utility:

When selecting an antibody, researchers should consider which parameters are most critical for their specific experimental needs and review validation data for their application of interest .

What are the recommended protocols for using CLNS1A antibodies in Western blot applications?

For optimal Western blot results with CLNS1A antibodies:

Sample Preparation:

• Extract proteins from cells using standard lysis buffers containing protease inhibitors

• Load 25μg of total protein per lane for cell line extracts

Antibody Conditions:

• Primary antibody dilution: 1:500-1:1000 is typically recommended

• For HPA032045 (Sigma), use 0.04-0.4 μg/mL

• Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:10000 dilution

Detection Protocol:

• Block membrane with 3% nonfat dry milk in TBST

• Incubate with primary antibody overnight at 4°C

• Wash 3x with TBST

• Incubate with secondary antibody for 1 hour at room temperature

• Detect using ECL enhanced chemiluminescence kit

• Expected band size: approximately 26-38 kDa

Validation data shows detection of CLNS1A in various cell lines, indicating widespread expression .

How should CLNS1A antibodies be optimized for immunohistochemistry applications?

For successful CLNS1A immunohistochemistry:

Sample Preparation:

• FFPE (formalin-fixed paraffin-embedded) tissue sections should be deparaffinized and rehydrated

• Antigen retrieval is critical: use citrate buffer pH 6.0 with heat-induced epitope retrieval

Staining Protocol:

• Recommended dilution: 1:20-1:50 for most polyclonal antibodies

• For Prestige Antibodies (HPA032045): 1:200-1:500

• Incubation time: 1-2 hours at room temperature or overnight at 4°C

• Detection system: Use a polymer-based detection system appropriate for the host species

Controls:

• Always include a positive control tissue known to express CLNS1A

• Include a negative control by omitting primary antibody

• Consider using tissues from CLNS1A knockout models as specificity controls if available

The Human Protein Atlas project has validated several CLNS1A antibodies across 44 normal human tissues and 20 common cancer types, providing excellent reference data .

What are the optimal storage and handling conditions for maintaining CLNS1A antibody activity?

Proper storage is critical for maintaining antibody performance over time:

Long-term Storage:

• Store at -20°C for up to one year

• Avoid repeated freeze-thaw cycles

• Aliquot antibodies upon first use to minimize freeze-thaw cycles

Short-term Storage:

• For frequent use within one month, store at 4°C

Working Solutions:

• Prepare fresh dilutions on the day of experiment

• Return stock solutions to recommended storage temperature immediately after use

Buffer Composition:

• Most CLNS1A antibodies are provided in PBS (pH 7.2) with 40-50% glycerol and 0.02% sodium azide

• This formulation helps maintain stability during freeze-thaw cycles

Following these guidelines will help preserve antibody activity and ensure consistent experimental results over time.

How can CLNS1A antibodies be used to study protein-protein interactions in the methylosome complex?

CLNS1A functions as part of the methylosome complex with PRMT5 and WDR77, making it an important target for protein interaction studies:

Co-Immunoprecipitation Approach:

• Lyse cells in a buffer containing 150mM NaCl, 50mM Tris pH 7.5, 0.5% NP-40, and protease inhibitors

• Pre-clear lysate with protein A/G beads

• Incubate with CLNS1A antibody (2-5μg) overnight at 4°C

• Add protein A/G beads and incubate for 1-2 hours

• Wash extensively with lysis buffer

• Elute and analyze by Western blot for PRMT5, WDR77, or other potential interactors

Proximity Ligation Assay:

• Use CLNS1A antibody in combination with antibodies against PRMT5 or WDR77

• This technique allows visualization of protein interactions in situ with high specificity

Validation Strategy:

• Implement controls including IgG-only immunoprecipitation

• Consider knockdown of CLNS1A to confirm specificity of interactions

• Use recombinant proteins to confirm direct interactions in vitro

Recent research indicates that CLNS1A participates in the PRMT5-mediated methylation events involved in mTORC1 regulation through methionine sensing pathways .

What approaches can be used to validate the specificity of CLNS1A antibodies?

Rigorous validation is essential for ensuring reliable results with CLNS1A antibodies:

Multiple Validation Techniques:

• Protein Array Testing:

  • High-quality antibodies should be tested against protein arrays containing the target protein and hundreds of non-specific proteins

  • Example: Prestige Antibodies are validated on arrays with 364 human recombinant protein fragments

• Genetic Validation:

  • Use CRISPR-Cas9 CLNS1A knockout or knockdown cells

  • Observe disappearance of the target band/signal in Western blot or immunostaining

  • This represents the gold standard for antibody validation

• Immunogen Blocking:

  • Pre-incubate antibody with the immunogen peptide

  • Signal should be significantly reduced in the presence of the blocking peptide

  • Note that blocking peptides can be purchased for some antibodies

• Multiple Antibody Concordance:

  • Compare results from different antibodies targeting distinct epitopes of CLNS1A

  • Concordant results increase confidence in specificity

• Mass Spectrometry Validation:

  • Immunoprecipitate CLNS1A and confirm identity by mass spectrometry

  • This approach provides unambiguous identification of the target protein

Companies like Boster Bio and Sigma-Aldrich provide validation images and technical information that can help assess antibody specificity before purchase .

What are the most common problems encountered when using CLNS1A antibodies and how can they be resolved?

When working with CLNS1A antibodies, researchers may encounter several common issues:

Problem 1: Weak or No Signal in Western Blot

• Potential Causes: Insufficient protein loading, degraded protein, inefficient transfer, improper antibody dilution

• Solutions:

  • Increase protein loading to 30-50μg per lane

  • Add fresh protease inhibitors during sample preparation

  • Optimize transfer conditions for proteins in the 26kDa range

  • Reduce antibody dilution (e.g., from 1:1000 to 1:500)

  • Try enhanced chemiluminescence detection systems

Problem 2: Non-specific Bands in Western Blot

• Potential Causes: Cross-reactivity, secondary antibody issues, sample contamination

• Solutions:

  • Increase blocking concentration to 5% BSA or milk

  • Extend blocking time to 2 hours at room temperature

  • Perform more stringent washing steps

  • Consider using a different CLNS1A antibody targeting a different epitope

Problem 3: High Background in Immunohistochemistry

• Potential Causes: Insufficient blocking, too concentrated antibody, endogenous peroxidase activity

• Solutions:

  • Optimize blocking conditions (3% BSA, 1 hour)

  • Dilute primary antibody further (1:50 to 1:200)

  • Include a peroxidase quenching step

  • Reduce incubation time with substrate

Problem 4: Variability Between Experiments

• Potential Causes: Antibody degradation, inconsistent sample preparation

• Solutions:

  • Aliquot antibody to avoid freeze-thaw cycles

  • Standardize sample preparation protocols

  • Include internal loading controls

  • Consider using automated systems for consistent results

How can researchers optimize CLNS1A detection in challenging samples or conditions?

Challenging samples require additional optimization strategies:

For Low Expression Levels:

• Use signal amplification systems such as tyramide signal amplification for IHC/IF

• Extend exposure time for Western blots

• Enrich for CLNS1A by subcellular fractionation or immunoprecipitation before detection

• For Western blots, consider using PVDF membranes which may provide better protein retention than nitrocellulose

For Fixed Tissue Samples:

• Test different antigen retrieval methods:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Tris-EDTA buffer (pH 9.0)

  • Enzymatic retrieval with proteinase K

• Optimize fixation protocol if possible (shorter fixation times may preserve epitopes)

• Consider using amplification systems like HRP-polymer detection

For Co-localization Studies:

• Select antibodies raised in different host species to avoid cross-reactivity

• Use highly cross-adsorbed secondary antibodies

• Include appropriate controls to confirm specificity of staining

• Consider super-resolution microscopy techniques for detailed co-localization analysis

For Clinical Samples:

• Validate antibodies specifically on the tissue/sample type of interest

• Compare results across multiple antibodies targeting different epitopes

• Include appropriate positive and negative controls from similar sample types

How can CLNS1A antibodies be used to investigate its role in spliceosomal snRNP assembly?

CLNS1A is critical for spliceosomal assembly, making antibodies valuable tools for studying this process:

Experimental Approaches:

• Immunoprecipitation-based snRNP Assembly Analysis:

  • Use CLNS1A antibodies to immunoprecipitate protein complexes

  • Analyze associated snRNAs by RT-PCR or sequencing

  • Identify protein components by Western blot or mass spectrometry

  • This approach can reveal the composition of CLNS1A-associated snRNP complexes

• Proximity-dependent Labeling:

  • Generate CLNS1A fusions with BioID or APEX2

  • Identify proximal proteins during snRNP assembly

  • Validate interactions using co-immunoprecipitation with CLNS1A antibodies

• Sequential Immunoprecipitation:

  • First IP with CLNS1A antibody

  • Elute and perform second IP with antibodies against Sm proteins

  • This approach can identify intermediate complexes in the assembly pathway

• Imaging-based Approaches:

  • Use CLNS1A antibodies for immunofluorescence

  • Co-stain with markers of Cajal bodies or other snRNP assembly sites

  • Perform live-cell imaging with tagged CLNS1A to track assembly dynamics

  • Compare localization patterns before and after blocking specific interactions

Recent studies have shown that CLNS1A traps Sm proteins (SNRPD1, SNRPD2, SNRPE, SNRPF, and SNRPG) in an inactive 6S complex, controlling core snRNP assembly . CLNS1A antibodies can help elucidate these regulatory mechanisms.

What experimental designs can effectively investigate CLNS1A's involvement in the mTORC1 methionine sensing pathway?

Recent research has implicated CLNS1A in mTORC1 methionine sensing pathways, providing new research opportunities:

Experimental Design Options:

• CLNS1A-PRMT1-GATOR1 Interaction Studies:

  • Perform co-immunoprecipitation with CLNS1A antibodies under normal and methionine-starved conditions

  • Analyze changes in PRMT1 and GATOR1 component binding

  • Use Western blotting to detect associated proteins like NPRL2 and NPRL3

  • Include controls with methionine metabolites (SAM, SAH) to assess their effects on complex formation

• Lysosomal Translocation Assays:

  • Use subcellular fractionation to isolate lysosomal fractions

  • Probe for CLNS1A, PRMT5, and mTOR under different methionine conditions

  • Perform immunofluorescence with CLNS1A antibodies co-stained with lysosomal markers

  • Quantify co-localization before and after methionine stimulation

• Methylation Activity Measurement:

  • Immunoprecipitate CLNS1A-associated complexes

  • Perform in vitro methylation assays on known substrates

  • Compare activity under different SAM/SAH ratios

  • Use methylation-specific antibodies to detect changes in substrate methylation

• Functional Pathway Analysis:

  • Monitor mTORC1 signaling (phospho-S6K, phospho-4EBP1) after CLNS1A knockdown

  • Rescue experiments with wild-type versus mutant CLNS1A

  • Design experiments that distinguish between CLNS1A's role in methylosome function versus direct mTORC1 regulation

Integrating these approaches can provide comprehensive insights into CLNS1A's role at the intersection of RNA processing and metabolic sensing .

What are the best experimental controls when using CLNS1A antibodies for research applications?

Rigorous controls are essential for generating reliable data with CLNS1A antibodies:

Essential Control Types:

Application-specific Controls:

• For Co-immunoprecipitation:

  • Include "beads only" control

  • Use non-specific IgG of same species as CLNS1A antibody

  • Include washing controls to establish stringency

• For Immunohistochemistry:

  • Use tissues with known CLNS1A expression patterns

  • Include parallel sections with isotype control

  • Consider absorption controls with immunizing peptide

• For Functional Studies:

  • Complement antibody-based approaches with genetic manipulation

  • Include both gain-of-function and loss-of-function experiments

  • Use domain-specific mutants to map functional interactions

Implementing these controls ensures that observations are specifically attributable to CLNS1A and not experimental artifacts.

What emerging applications of CLNS1A antibodies show promise for advancing understanding of cellular signaling pathways?

Several innovative applications of CLNS1A antibodies are emerging as valuable tools for studying complex cellular processes:

Emerging Applications:

• Proximity-dependent Labeling Technologies:

  • Combining CLNS1A antibodies with BioID or APEX2 systems

  • Mapping temporal changes in the CLNS1A interactome during cell cycle or stress responses

  • Identifying novel interaction partners in different subcellular compartments

  • This approach could reveal previously unknown functions beyond established roles in methylosome and snRNP assembly

• Single-cell Protein Analysis:

  • Using CLNS1A antibodies for CyTOF or CODEX multiplexed imaging

  • Correlating CLNS1A levels with cell state markers

  • Examining heterogeneity in expression and localization at single-cell resolution

  • This could identify cell populations with distinct CLNS1A-dependent functional states

• Phase Separation Studies:

  • Investigating CLNS1A's potential role in biomolecular condensates

  • Using super-resolution microscopy with CLNS1A antibodies

  • Examining co-localization with proteins involved in membraneless organelles

  • Recent studies suggest many RNA-binding proteins participate in phase separation processes

• Metabolic Sensing Pathway Integration:

  • Studying how CLNS1A connects methionine metabolism to splicing regulation

  • Using antibodies to track dynamic complex formation under different metabolic states

  • Correlating CLNS1A activity with SAM/SAH ratio fluctuations

  • This research direction could reveal novel regulatory mechanisms linking metabolism to RNA processing

These emerging applications promise to expand our understanding of CLNS1A's multifunctional roles in cellular signaling networks.

How might multi-omics approaches incorporating CLNS1A antibodies advance functional proteomics research?

Integrating CLNS1A antibody-based methods with other omics approaches can provide systems-level insights:

Multi-omics Integration Strategies:

• Antibody-based Proteomics with Transcriptomics:

  • Use CLNS1A antibodies for immunoprecipitation followed by mass spectrometry

  • Correlate protein interaction changes with alterations in splicing patterns (RNA-seq)

  • This integrated approach can connect CLNS1A's protein interactions with functional outcomes in RNA processing

• Spatial Proteomics:

  • Employ CLNS1A antibodies for multiplexed tissue imaging

  • Map CLNS1A distribution across different cell types and subcellular compartments

  • Correlate with metabolic state markers to understand context-dependent functions

  • Technologies like CODEX or Imaging Mass Cytometry enable highly multiplexed protein detection

• ChIP-seq Applications:

  • Use CLNS1A antibodies for chromatin immunoprecipitation

  • Map potential genomic associations, particularly if CLNS1A participates in transcriptional regulation

  • Integrate with RNA-seq data to correlate binding with expression changes

• Metabolic Proteomics:

  • Combine CLNS1A immunoprecipitation with metabolite analysis

  • Study how methionine metabolites affect CLNS1A complex formation

  • Link metabolic state changes to alterations in CLNS1A-dependent functions

  • This approach could provide mechanistic insights into how CLNS1A participates in methionine sensing

• Structural Biology Integration:

  • Use CLNS1A antibodies to stabilize protein complexes for cryo-EM studies

  • Generate Fab fragments for co-crystallization approaches

  • This could reveal structural details of CLNS1A's interactions with methylosome components

These integrative approaches can overcome limitations of single-method studies and provide comprehensive insights into CLNS1A's diverse cellular functions.